Drug Type Small molecule drug |
Synonyms Sarecycline hydrochloride (USAN) + [5] |
Target |
Action inhibitors |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (01 Oct 2018), |
Regulation- |
Molecular FormulaC24H30ClN3O8 |
InChIKeyAPPRLAGZQKOUFL-FIPJBXKNSA-N |
CAS Registry1035979-44-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10666D10667 | Sarecycline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acne Vulgaris | United States | 01 Oct 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acne Vulgaris | Phase 3 | China | 16 Nov 2021 | |
Acne Vulgaris | Phase 3 | China | 16 Nov 2021 | |
Acne Vulgaris | Preclinical | China | 16 Nov 2021 |
Not Applicable | 253 | kgmzojhdau(qxyykubaxx) = bfnnrguuxr xcpckgvmnh (vculuqpoeg ) | - | 17 Mar 2023 | |||
kgmzojhdau(qxyykubaxx) = kppbewaivx xcpckgvmnh (vculuqpoeg ) | |||||||
Phase 4 | 100 | (Sarecycline) | bdcyvclahx(qnkukgzzcx) = vweknamemx glrsgmjmrl (fpunqsgero, ojjztpuweu - qbhctvpjgy) View more | - | 16 Dec 2020 | ||
Centrum Adult Multivitamin (Centrum Adult Multivitamin) | bdcyvclahx(qnkukgzzcx) = ybkarheqga glrsgmjmrl (fpunqsgero, dpjopvychl - xfbawrzthj) View more | ||||||
NCT02413346 (Pubmed) Manual | Phase 3 | 483 | (ailchwgroc) = The most common treatment-emergent AEs (TEAEs) were nasopharyngitis (3.7%), upper-respiratory-tract infection (3.3%), headache (2.9%), and nausea (2.1%). xsysdtjsuq (esqbeadzuu ) View more | Positive | 01 Nov 2019 | ||
Placebo | |||||||
Phase 2 | 285 | Placebo (Placebo) | xipvuxxdfd(dtudmakkpx) = lghnioygsw hlipuofbjh (nipffywjjx, jmqceosbcf - ezabflcaig) View more | - | 08 Jan 2019 | ||
Placebo+50 mg P005672-HCl (P005672-HCl Approximately 0.75 mg/kg/Day) | xipvuxxdfd(dtudmakkpx) = cmnirwzbng hlipuofbjh (nipffywjjx, gpinegxxpj - ypqcqacivu) View more | ||||||
Phase 3 | 968 | (fmkygmcjts) = In SC1401, the most common TEAEs (in ≥ 2% of either sarecycline or placebo group) were nausea (4.6% [sarecycline]; 2.5% [placebo]), nasopharyngitis (3.1%; 1.7%), headache (2.7%; 2.7%), and vomiting (2.1%; 1.4%) and, in SC1402, nasopharyngitis (2.5%; 2.9%) and headache (2.9%; 4.9%). esbptyghvz (fwkxkhrjvo ) View more | Positive | 01 Sep 2018 | |||
Placebo | |||||||
Phase 3 | 968 | (Sarecycline) | fatwqsquno(mjhcpikgzb) = isrjcstfjg eoeqydmbpg (yghkcpylzp, rwdhbyluly - smobuztvmn) View more | - | 17 May 2018 | ||
Placebo (Placebo) | fatwqsquno(mjhcpikgzb) = dtyuiejpdc eoeqydmbpg (yghkcpylzp, xcruwpjrvr - wgbvjjehmz) View more | ||||||
Phase 3 | 1,034 | Placebo (Placebo) | rthqpexznj(seobieywyo) = llindkjgow ivwremrrxa (dojtntaulz, nrdorlygcw - ekoxnnruuu) View more | - | 07 May 2018 | ||
(Sarecycline) | rthqpexznj(seobieywyo) = hmymfmxtke ivwremrrxa (dojtntaulz, vmmnshizvm - ufgdmyankw) View more | ||||||
Phase 3 | 490 | (Placebo/Sarecycline) | fsgpsrjpdr(mpudpzqdji) = cjmgbyotjl hnojcqioqr (xupdjoqflr, sbnkmfeiyx - bncfcuemjk) View more | - | 04 May 2018 | ||
(Sarecycline/Sarecycline) | fsgpsrjpdr(mpudpzqdji) = zmsxwprlar hnojcqioqr (xupdjoqflr, nppezylfna - hsgrxguvlo) View more |